Follow
Oliver Cornely
Oliver Cornely
Verified email at uk-koeln.de
Title
Cited by
Cited by
Year
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
OA Cornely, J Maertens, DJ Winston, J Perfect, AJ Ullmann, TJ Walsh, ...
New England Journal of Medicine 356 (4), 348-359, 2007
20492007
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group …
OA Cornely, A Alastruey-Izquierdo, D Arenz, SCA Chen, E Dannaoui, ...
The Lancet infectious diseases 19 (12), e405-e421, 2019
13672019
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients
OA Cornely, M Bassetti, T Calandra, J Garbino, BJ Kullberg, O Lortholary, ...
Clinical Microbiology and Infection 18, 19-37, 2012
12862012
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
AJ Ullmann, JM Aguado, S Arikan-Akdagli, DW Denning, AH Groll, ...
Clinical Microbiology and Infection 24, e1-e38, 2018
12502018
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia
TJ Walsh, H Teppler, GR Donowitz, JA Maertens, LR Baden, ...
New England Journal of Medicine 351 (14), 1391-1402, 2004
11732004
Physiological plasticity increases resilience of ectothermic animals to climate change
F Seebacher, CR White, CE Franklin
Nature Climate Change 5 (1), 61-66, 2015
10272015
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
OA Cornely, DW Crook, R Esposito, A Poirier, MS Somero, K Weiss, ...
The Lancet infectious diseases 12 (4), 281-289, 2012
8622012
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
ER Kuse, P Chetchotisakd, CA da Cunha, M Ruhnke, C Barrios, ...
The Lancet 369 (9572), 1519-1527, 2007
8562007
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled …
JA Maertens, II Raad, KA Marr, TF Patterson, DP Kontoyiannis, ...
The Lancet 387 (10020), 760-769, 2016
8542016
Liposomal amphotericin b as initial therapy for invasive mold infection: a randomized trial comparing a high–loading dose regimen with standard dosing (AmBiLoad Trial)
OA Cornely, J Maertens, M Bresnik, R Ebrahimi, AJ Ullmann, E Bouza, ...
Clinical infectious diseases 44 (10), 1289-1297, 2007
8182007
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
MH Wilcox, DN Gerding, IR Poxton, C Kelly, R Nathan, T Birch, ...
New England Journal of Medicine 376 (4), 305-317, 2017
7732017
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013
OA Cornely, S Arikan‐Akdagli, E Dannaoui, AH Groll, K Lagrou, ...
Clinical Microbiology and Infection 20, 5-26, 2014
7252014
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
P Koehler, M Bassetti, A Chakrabarti, SCA Chen, AL Colombo, M Hoenigl, ...
The Lancet Infectious Diseases 21 (6), e149-e162, 2021
7162021
Mapping the human genetic architecture of COVID-19
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
7002021
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
FM Marty, L Ostrosky-Zeichner, OA Cornely, KM Mullane, JR Perfect, ...
The Lancet infectious diseases 16 (7), 828-837, 2016
6572016
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 update
J Maertens, O Marchetti, R Herbrecht, OA Cornely, U Flückiger, P Frere, ...
Bone marrow transplantation 46 (5), 709-718, 2011
6002011
COVID‐19 associated pulmonary aspergillosis
P Koehler, OA Cornely, BW Böttiger, F Dusse, DA Eichenauer, F Fuchs, ...
Mycoses 63 (6), 528-534, 2020
5812020
Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials
S Johnson, TJ Louie, DN Gerding, OA Cornely, S Chasan-Taber, D Fitts, ...
Clinical Infectious Diseases 59 (3), 345-354, 2014
5552014
Combination antifungal therapy for invasive aspergillosis: a randomized trial
KA Marr, HT Schlamm, R Herbrecht, ST Rottinghaus, EJ Bow, OA Cornely, ...
Annals of internal medicine 162 (2), 81-89, 2015
5122015
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
OA Cornely, MA Miller, TJ Louie, DW Crook, SL Gorbach
Clinical infectious diseases 55 (suppl_2), S154-S161, 2012
5022012
The system can't perform the operation now. Try again later.
Articles 1–20